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Abstract
Background: Chikungunya virus (CHIKV) is responsible for acute febrile polyarthralgia and, in a proportion of cases, severe
complications including chronic arthritis. CHIKV has spread recently in East Africa, South-West Indian Ocean, South-Asia and
autochthonous cases have been reported in Europe. Although almost all patients are outpatients, medical investigations
mainly focused on hospitalised patients.
Methodology/Principal Findings: Here, we detail clinico-biological characteristics of Chikungunya (CHIK) outpatients in
Reunion Island (2006). 76 outpatients with febrile arthralgia diagnosed within less than 48 hours were included by general
practitioners during the CuraChik clinical trial. CHIK was confirmed in 54 patients and excluded in 22. A detailed clinical and
biological follow-up was organised, that included analysis of viral intrahost diversity and telephone survey until day 300. The
evolution of acute CHIK included 2 stages: the ‘viral stage’ (day 1–day 4) was associated with rapid decrease of viraemia and
improvement of clinical presentation; the ‘convalescent stage’ (day 5–day 14) was associated with no detectable viraemia
but a slower clinical improvement. Women and elderly had a significantly higher number of arthralgia at inclusion and at
day 300. Based on the study clinico-biological dataset, scores for CHIK diagnosis in patients with recent febrile acute
polyarthralgia were elaborated using arthralgia on hands and wrists, a minor or absent myalgia and the presence of
lymphopenia (,1G/L) as major orientation criteria. Finally, we observed that CHIKV intra-host genetic diversity increased
over time and that a higher viral amino-acid complexity at the acute stage was associated with increased number of
arthralgia and intensity of sequelae at day 300.
Conclusions/Significance: This study provided a detailed picture of clinico-biological CHIK evolution at the acute phase of
the disease, allowed the elaboration of scores to assist CHIK diagnosis and investigated for the first time the impact of viral
intra-host genetic diversity on the disease course.
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Introduction
Chikungunya virus (CHIKV) is an arbovirus (genus Alphavirus,
family Togaviridae), transmitted by the bite of infected mosquitoes
(Aedes aegypti= Stegomya aegypti and Aedes albopictus= Stegomya
albopicta), that causes Chikungunya fever (CHIK), an acute febrile
illness characterized by severe and often debilitating arthralgia [1].
CHIKV was first isolated in 1952 in East-Africa [2]. The name
‘Chikungunya’ refers to the stooped posture that develops in an
individual as a result of arthritic symptoms and comes from the
Bantu language of the Makonde people (Tanzania and Mozam-
bique) [2]. Until recently, knowledge of CHIK clinical features
was based on its first description in the 1970s [3,4]. Since 2005,
CHIK outbreaks of unprecedented magnitude have occurred in
South-Asia and the Indian Ocean islands, including Reunion
Island with an estimated 266,000 cases, accounting for roughly
one third of the population [5]. In 2007, a viraemic traveller from
India introduced CHIKV into northern Italy, resulting in an
outbreak with 292 suspected cases [6]. Thus, CHIK constitutes a
serious threat numerous tropical and temperate areas due to the
fact that Aedes albopictus is now widespread, notably in Southern-
Europe [6,7], and displays seasonal synchronicity within potential
endemic areas [8].
Although almost all CHIK patients are outpatients, most
clinical and laboratory investigations of CHIK focused on
hospitalised patients (i.e. mostly with severe presentations that
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represented a very small proportion of total infections)
[9,10,11,12]. Our attempts to describe the clinical and biological
features of chikungunya acute disease took advantage of data
collected during the CuraChik clinical trial, performed on
Reunion Island during the 2006 Indian Ocean outbreak [13].
CuraChik provided a unique opportunity to collect detailed
clinical and biological information from CHIKV infected patients
with the most common forms of clinical presentation, recruited by
general practitioners.
Materials and Methods
Objectives
(i) We aimed to provide a precise clinical and biological
description of acute laboratory-confirmed CHIKV infection
in outpatients and some information regarding follow-up
until day 300.
(ii) We also compared CHIKV positive and negative patients
recruited on the basis of clinical presentation with acute
febrile arthralgia during an epidemic period.
(iii) We finally performed a comprehensive comparative analysis
of intra-host viral genetic diversity.
Study design
Patients and procedures. The main details of the CuraChik
trial have been reported elsewhere [14]. Curachik (http://
clinicaltrials.gov/ct2/show/NCT00391313) was a randomised
double blind, placebo-controlled, prospective trial aiming at
evaluating the efficacy and safety of chloroquine as therapeutic
treatment of CHIK (study protocol available on File S1).
This trial included adult patients (18–65 years old, men and
women), who volunteered to take part in the study, residing in
Reunion Island, having a typical presentation of acute CHIK
(defined by acute febrile arthralgia) diagnosed within less than
48 hours. Exclusively general practitioners (GPs) enrolled the
eligible patients.
Clinical data were collected from three sources: (i) a daily auto-
questionnaire from day 1 (D1) to day 14 (D14); (ii) three
consultations with a GP on D1, day 7 (D7) (mean 6.4, SD=1.4)
and day 25 (D25) (mean 26.5, SD=9.8); (iii) a telephone
questionnaire on day 100 (D100) (mean 130.5, SD=28.1) and
day 300 (D300) (mean 300.7, SD=13.8).
Biological data were collected from the analysis of blood
samples on D1, D3, D6 and D16. The extraction of nucleic acids
and CHIKV specific RT-PCR [15] were carried out from all
samples (D1, D3, D6 and D16). Tests for the presence of CHIKV-
specific immunoglobulin G (IgG) and IgM were performed at D1,
D6 and D16 by an indirect immunofluorescence assay (according
to a procedure previously described [16]).
The case definition of CHIKV positive patients relied on the
association of a CHIKV specific positive RT-PCR on D1 and
seroconversion on D16. CHIK negative patients tested negative
for CHIKV genome on D1 and showed no evidence of
seroconversion on D16.
Ethics Statement. The study commenced on May 20, 2006,
after obtaining authorisation from the French Health Products
Safety Agency and Ethics Committee. All subjects provided
informed written consent.
Intra-host viral genetic diversity. Ten patients with a
variety of clinical and biological presentations and a positive
CHIKV RT-PCR diagnostic test were selected within the placebo
subgroup. The extraction of nucleic acids was performed from D1
and D3 sera using the EZ1 virus MiniKit (virus card 2.0) and an
EZ1 biorobot (Qiagen, Germany) according to the manufacturer’s
protocol. For all patients (n = 10), a 692-nucleotide fragment
within the E1 gene (positions 10138–10829) was amplified using
the high fidelity Eppendorf One-Step RT-PCR kit and primers
CV1F (59-CTATCGCTTGATTACATCACG-39) and CV1R
(59-CGCTTCCGGTATGTCGATG-39). This fragment includes
amino acidsspanning position E1/226. The mutation A226V has
been reported to confer a virus adaptation to Aedes albopictus
[17,18]. Analysis was also performed for samples collected at D3
for 2 patients still viraemic at this time. Amplification products
were purified (QIAquick PCR Purification Kit), subjected to 39
end adenosine addition (Taq polymerase, Invitrogen), ligated into
the cloning vector pCR 2.1 and transformed into TOP10
competent cells, according to the manufacturer’s protocol (TA
Cloning, Invitrogen). An average of 45 clones per serum sample
was sequenced directly from the plasmid using the T7 promoter
primer (59-CCCTATAGTGAGTCGTATTA-39).
Sequences were analysed with the Sequencher software and
aligned with ClustalX [19]. For a given sample, the sequence of
each clone was compared with the most common sequence using
the Mega 4.1 programme [20]. Differences in nucleotide and
protein sequences were analysed according to different clinical,
biological or demographic parameters. Sequence divergence was
evaluated using the pairwise distance among nucleotide (p nt) and
amino acid (p aa) sequences. The mean ratio of non-synonymous
(dN) to synonymous (dS) substitutions per site was estimated using
the pairwise method of Nei and Gojobori [21] in MEGA. For the
analysis of intra-host genetic diversity, the sequence of each clone
was compared to all other clones for each human serum. The
percentage of variable nucleotide sites (number of variable nt sites/
number of nt sites), of nucleotide mutations (number of nt
mutation/number of nt sequenced), and of mutant clones (number
of clones with mutation/total number of clones) was calculated, as
well as the p nt, p aa, dN, dS and dN/dS parameters.
Statistical analysis and diagnostic score. To assess factors
relating to clinical presentation and laboratory abnormality during
CHIK on D1 and D300, we performed univariate analysis, for
Author Summary
The mosquito-transmitted chikungunya virus is responsi-
ble for acute febrile polyarthralgia and, in a proportion of
cases, complications including chronic arthritis. Since 2005,
it has massively re-emerged in the Old World. Although
the large majority of patients are outpatients, the most
detailed studies have focused previously on hospitalised
patients (i.e., severe cases). Here, we report the detailed
clinico-biological characteristics of ‘standard’ clinical pre-
sentations in patients followed-up by general practitioners
in Reunion Island (2006) during the CuraChik clinical trial.
At the onset of the disease, two stages were observed: (i) a
‘viral stage’ during the first 4 days, associated with an
acute febrile polyarthralgic syndrome and a subsequent
rapid clinical improvement; the main clinico-biological
characteristics during that period were used to elaborate
supportive chikungunya diagnostic scores, (ii) a ‘convales-
cent stage’ (days 5–14) with no detectable viraemia but a
slower clinical improvement. Woman and elderly patients
were found at risk for more symptomatic forms of the
disease at both the acute and late stages (day 300) and we
observed that the viral intra-host genetic diversity
increased over time and that a higher viral amino-acid
complexity at the acute stage was associated with more
symptomatic illness at the late stage of the disease.
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qualitative factors with Fisher’s exact test and for continuous
factors using the Mann Whitney nonparametric test. Correlations
were assessed using the Spearman nonparametric test. Following
the Mickey and Greenland approach [22], variables with P-values
,0,2 were retained and entered into backwards stepwise
multivariate linear regression models (logistic, Gaussian or Poisson
regression depending on the dependent variable, respective
percentage, continuous or count variable), following the Mickey
and Greenland approach [22]. The standard deviation (SD) and
95% confidence interval (CI) of the odds ratio (OR) (logistic
regression), the linear regression coefficient (b) (Gaussian regres-
sion) and the Standardized Incidence Ratio (SIR, Poisson
regression) were estimated.
To compare the intra-host diversity and the available clinical
and laboratory data, we performed correlation analyses using the
Spearman nonparametric test.
Finally, we evaluated the possibility of generating a diagnostic
score of CHIK on the first day of monitoring, by comparing the
clinical and biological features of CHIKV positive and negative
samples. Any factor for which a Pearson’s chi2 or Fisher test was
,0.2, was included in multivariate analysis (hierarchical log-linear
model) to study the adjusted relationship between different
variables and their interactions. Sensitivities (Se), specificities
(Sp), predictive values - positive (PPV) and negative (NPV) - were
estimated and yielded a Receiver Operating Characteristic (ROC)
curve and the area under the curve (AUC).
All statistical analyses were performed with the IBM SPSS
statistic 19 software.
For multivariate analysis, the alpha probability threshold of
significance was 0.05.
Results
Population studied
Amongst 76 patients included at D1, the diagnosis of CHIKV
was confirmed in 54 patients (CHIKV+ve patients) and excluded
in 22 patients (CHIKV2ve patients). Since the clinical and
biological assessment at D1 was obtained prior to the beginning of
the treatment, all CHIKV+ve patients could be used for analysis at
the time of inclusion. By contrast, only the patients who received
the placebo (27 CHIKV+ve and 13 patients CHIKV2ve, placebo
group) were used to describe the evolution of the disease.
Clinical presentation at inclusion. Amongst CHIKV+ve
patients (54 patients), the mean age was 40 years old, the sex ratio
(m/f) was 1.7 and the mean weight was 76.1 kg (Table 1). The
average time between symptom onset and inclusion was 1.2 days
(ranging between 0–2, SD=0.595) reflecting the initial stage of
illness. Five (9.3%) patients had pre-existing orthopaedic illness.
The most common presenting clinical symptom was a febrile
poly-arthralgia (16 joints on average, out of 34 on the proposed
diagram, SD=10, median= 17) with an intensity assessed as
important (among 4 categories: absent, minimal, moderate,
important) in 46.3%. Arthralgia was symmetrical (i.e., bilateral)
in 53.7% of cases and small joints were more frequently affected
(hands 79.6%, wrist 72.2%, ankles 68.5%, knees 61.1%, lumbar
46.3%, shoulders 48.1%, feet 42.6%, cervix 38.9%, elbows 25.9%)
(Table 1). No arthralgia lateralization according to right-handed
or left-handed was noted. General symptoms were most often
recorded as headache (72%), asthenia (76%), myalgia (74%) and
chills (83%).
Few other signs were noted: dermatological signs (28%),
digestive disorders such as nausea/vomiting (44%), diarrhoea
(22%) and dysgeusia (13%) (Figure 1).
Quality of life (assessed by visual analogical scales (VAS)) was
severely impacted with the capacity to perform normal activities,
health status and quality of sleep assessed on average at 33/100
(SD=26), 28/100 (SD=25) and 27/100 (SD=13), respectively.
More than half of the patients scored ,30/100 in all aspects of
quality of life evaluation (Figure 2).
Demographic and biological data were compared as functions
of clinical presentation at D1 using multivariate analysis. A higher
number of arthralgic joints was independently associated with
women (p,0.001, SIR= 1.361, CI (1.191;1.554)), with an increase
of age (p,0.001, SIR= 1.017, CI (1.011;1.022)) and a decrease of
leukocytosis (p,0.001, SIR=0.881 CI(0.841;0.923)). Patients with
important arthralgia were significantly older than others (p,0.05,
OR=1.073, CI (1.013;1.136)) and associated with a shorter time
between onset of symptom and inclusion (p,0.05, OR=0.288, CI
(0.071;0.764)). Regarding quality of life no significant association,
in multivariate analysis with any risk factor analysed, could be
identified.
Biological presentation at inclusion
Lymphopenia was frequent at inclusion (94% of cases with a
value ,1.5 Giga per Litre (G/L); 79.6% with a value ,1 G/L).
Thrombocytopenia (,150 G/L) was noted in 24% of cases and
neutropenia (,2.5 G/L, but always .1 G/L) in 33% of cases.
Abnormal liver function (ALT .45 International Unit per Litre
(IU/L) and AST .35 IU/L) was found in 14% and 28%
respectively. C Reactive Protein (CRP) was .15 mg/L in 82% of
cases, .50 mg/L in 33% and .100 mg/L in 12% (Table 1).
There was no leukocytosis (.10 G/L). Five patients had anaemia
(,12 g/dl), including one patient had sickle disease (8 g/dl).
The average viral load at D1 was 1.26109 (3.76105–1.461010,
SD=2.36109 RNA copies/ml).
In multivariate analysis, a lower lymphocytosis was associated
with a shorter time between onset of symptoms and inclusion
(p = 0.053, b=0.249, CI(20.03;0.502)) and a higher viral load
(p,0.05, b=20.144, CI(20.284;20.004)). A higher viral load
was associated with an increase of age (p,0.05, b=0.024,
CI(0.001;0.047)) and a decrease of delay of inclusion (p,0.05,
b=20.608, CI(21.093;20.124)).
Clinical and biological evolution. There was no hospital-
isation during the 14-day follow-up and two clinical stages of
evolution were observed (Figures 2 and 3):
(i) From D1 to D4, a rapid improvement was observed (the
percentage of patients with arthralgia decreased from 98% to
68%, the average number of arthralgic joints decreased from
16 to 9 (SD=8,7), VAS quality of life scores increased more
than twice and the percentage of VAS ,50/100 decreased
from 83% to 19%).
(ii) From D5 until D14, the evolution was slower (68% of patient
still suffered from arthralgia on D14 with an average number
of 6 painful joints per person (SD=7,2), VAS quality of life
was assessed at 82/100 on average, with less than 5% of VAS
,50).
At the last medical visit (D25), 36% of patients reported residual
asthenia; 65% reported arthralgia (corresponding to 71% with
sporadic and 57% with permanent arthralgia respectively) while
44% and 32% of patients were assessed by GPs as recovered or
improved in condition respectively.
The number of patients with positive viraemia decreased from
54 (100%) on D1 to 21 (39.6%) on D3 and the average viral load
was 6.42 (4.43 to 9, SD=1.19, log10 copies/ml). In all cases there
was a decrease of viraemia from D1 to D3. At D6, all viral loads
Chikungunya Fever: An Outpatient Investigation
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were negative. At D16, there was neither lymphopenia nor
thrombocytopenia, while neutropenia and abnormal liver function
persisted in 12% and 7% of patients respectively. CRP was
.5 mg/L in 12% of cases without exceeding 50 mg/L.
During the D300 telephone interview, 5 out of 26 patients who
could be contacted (19.2%) considered that they had not
completely recovered; 6/26 (23%) declared residual arthralgia (7
joints on average, SD=5.3); morning stiffness was assessed in 4/6
(66.7%) cases but arthralgia was always related to joint activity.
Retrospectively, the duration of initial illness was estimated at
more than 4 weeks by 12 out 21 patients who considered that they
had completely recovered (57.1%). In univariate analysis, patients
who did not report recovery at D300 were older (p,0.05,
52.80612.61 vs 35.62610.56) and more frequently women
(p,0.05, women 60.0% (3/5); men 9.5% (2/21)). Patients who
reported persistent arthralgia at D300 were older (p,0.01,
51.33611.84 vs 35.20610.65) and had a higher number of
arthralgic joints at D1 (p,0.05, 23.5066.75 vs 12.2569.86). In
multivariate analysis, the number of painful joints at D300 was
higher for women (p= 0.065, SIR= 1.841, CI (0.963;3.520)) and
increased with age (p,0.001, SIR= 1.142, CI (1.103;1.183)).
Diagnostic score, comparison between CHIKV+ve and
CHIKV2ve patients. Analysis of the CHIKV+ve and
CHIKV2ve groups at baseline revealed no difference in the
Table 1. Clinical and biological characteristics of Curachik patients*.
CHIKV+ n (%) CHIKV2 n (%) p-Value Odd Ratio (95% CI)
Age
Mean (SD, min-max) 40.1 (12.4, 18–66) 41.4 (15.3, 20–66) 0.92
18–20 4 (7.4) 1 (4.5)
21–30 9 (16.7) 9 (40.9)
31–40 19 (35.2) 2 (9.1)
41–50 10 (18.5) 3 (13.6)
51–60 8 (14.8) 3 (13.6)
61–66 4 (7.4) 4 (18.2)
Gender N (%)
Male 34 (63) 11 (50) 0.3
Female 20 (37) 11 (50)
pre-existing orthopaedic illness 5 (9.3) 5 (22.7) 0.1
Localisation of Arthralgia
Metacarpophalangean (MCP) 40 (74.1) 9 (40.9) ,0.01 0.24 (0.09;0.69)
Interphalangean (PIP) 37 (68.5) 9 (40.9) 0.038 0.32 (0.11;0.89)
Hands (MCP+PIP) 43 (79.6) 10 (45.5) ,0.01 0.21 (0.07;0.62)
Wrist (W) 39 (72.2) 8 (36.4) ,0.01 0.22 (0.07;0.63)
Ankles 37 (68.5) 11 (50) 0.2
Knees 33 (61.1) 17 (77.3) 0.2
Shoulders 26 (48.1) 11 (50) 1.
Lombalgia 25 (46.3) 12 (54.5) 0.6
Feet 23 (42.6) 4 (18.2) 0.06 0.30 (0.089;1.01)
Cervicalgia 21 (38.9) 9 (40.9) 1.
Elbows 14 (25.9) 10 (45.5) 0.11
Myalgia
moderate or important 25 (46.3) 18 (81.8) ,0.01 5.22 (1.56;17.48)
Neutropenia (,2 G/l) 12 (22.2) 2 (10) 0.32
Lymphocytes (,1G/l) 43 (79.6) 4 (20) ,0.001 0.06 (0.02;0.23)
Mean (SD, min-max) 0.8 (0.57, 0.3–4) 1.5 (0,59, 0.6–2.7) ,0.001
Platelets (,150G/l) 14 (25.9) 1 (5) 0.055 0.15 (0.018;1.23)
Mean (SD, min-max) 185 (58.5, 104–348) 217 (54,5, 148–362) 0.014
C-Reactive Protein (CRP) (mg/l)
Mean (SD, min-max) 52.4 (42.4, 7–195) 51.8 (63.8, 0–264) 0.26
ASAT/ALAT .45 UI/l 11 (22) 0 (0) 0.028 0.78 (0.67;0.9)
*This trial included adult patients (18–65 years old) with a typical presentation of acute chikungunya disease (defined by acute febrile arthralgia) diagnosed within less than
48 hours. Exclusively general practitioners (GPs) enrolled the eligible patients, during the 2006 CHIKV outbreak on Reunion Island.
The case definition of CHIKV positive patients relied on the association of a chikungunya-specific positive RT-PCR on D1 and seroconversion on D16 ; the case definition of
CHIKV negative patients relied on the association of a chikungunya-specific negative RT-PCR on D1 and negative serology on D16. Laboratory confirmed chikungunya cases
(CHIKV+, 54 patients) were compared with those excluded (CHIKV2, 22 patients).
doi:10.1371/journal.pntd.0002004.t001
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distribution of age, sex, weight or time of inclusion (Table 1). In
univariate analysis, CHIKV+ve patients had:
(i) more frequent pain in small upper joints (wrists, W)
(p,0.01, OR=4.55, CI(1.59;13.04)), metacarpophalangeal
(MCP) (p,0.01, OR= 4.13, CI(1.45;11.74), proximal
interphalangeal (PIP) (p,0.05, OR=3.14 CI(1.13;8.77)),
(ii) more frequently minor or absent myalgia (MYOPAIN)
(p,0.01, OR=5.22, CI(1.56;17.48))
(iii) more frequently lymphopenia (,1 G/L) (p,0.0001,
OR=15.64, CI(4.35;56.25)).
Factors that showed a direct relationship in univariate and
multivariate analyzes with CHIK diagnosis were W, MCP,
MYOPAIN and lymphopenia. CHIKV+ve and CHIKV2ve
patients were not statistically different for the impact on quality
of life at the acute stage.
Finally, the probability (p) of having been infected by CHIKV
has been estimated, using logistic regression, as follows:
p= 1/(1+exp(4.139)6exp(23.6666lymphopenia)6exp(21.9406
MCP+)6exp(22.3416W+)6exp(22.7006MYOPAIN)). Each co-
variate was validated if equal to 1, otherwise 0. Tested on our
cohort, the ROC curve had an AUC=0.93 (p,0.001), with
Se= 90%, Sp=85%, PPV=94% and NPV=77% using a 0.579
probability threshold value.
Similarly, we could calculate a clinical score relying only on
clinical symptoms (i.e., excluding lymphopenia) : p = 1/(1+exp
(1.609)6exp(21.4506MCP+)6exp(21.7326W+)6exp(22.0446
MYOPAIN)). Tested on our cohort, the ROC curve had an
AUC=0.81 (p,0.001) and with Se = 76%, Sp= 73%,
PPV= 87% and NPV=55% using a 0.717 probability threshold
value.
Noticeably, in both scores, the variable Handpain (pain on
MCP and/or PIP) could be used instead of the MCP variable with
similar results.
Finally, these results were used to propose a clinical and clinico-
biological score usable in ambulatory practice by GPs (see on
Figure 4). The values of the score presented in Figure 4
represented, in our cohort, the predicted probability of having
been infected by CHIKV, with each score.
Intra-host viral genetic diversity. To investigate the intra-
host genetic diversity of CHIKV we sequenced, on average, 45
clones/serum (41–57) within the E1 gene (Table 2). For the 10
D1 sera, the average proportion of mutant clones observed was
35.6%, the mutations occurred in 10 (1.4%) to 27 (3.9%) sites of
the 692 nucleotides sequenced and the average proportion of non-
synonymous mutations was 73.2%. Forty-eight (24%) mutations
were observed more than once (41 twice, 7 in three clones). The
transition/transversion ratio was 5.8 (219:38). The average dN/dS
ratio (that illustrates selective pressure [23]), was 1.03 and 0.16 at
the intra-host and inter-host level, respectively. Over a total of 519
clones studied, the A226V mutation was found in all but one clone
(99.8%) and in-frame stop codons were identified in 2 clones
(0.4%).
Analysis of CHIKV intra-host genetic diversity was conducted
according to demographic, clinical and biological data (Table 2).
The major findings were:
(i) An increased percentage of mutant clones and average p
aa and dN was significantly correlated with an increased
delay between onset of disease and inclusion (p = 0.045 for
% of mutant clones, p,0.001 for p aa and dN).
(ii) A high viral load at D1 was significantly correlated with a
low intra-host diversity (p,0.01 for % of mutant clones,
Figure 1. Clinical features of ambulatory CHIKV+ve patients* at days 1, 7 and 25. These clinical data were collected from three
consultations with a general practitioner on day 1, day 7 (mean 6.4, SD=1.4) and day 25 (mean 26.5, SD=9.8) of the disease during the Reunion
island outbreak 2005–2006. * Since clinical assessment during the first medical visit was obtained prior to the beginning of the treatment, all
CHIKV+ve patients (N= 54) could be used for analysis. By contrast, only patients who received the placebo (N= 27) were included in the study of
disease evolution (second and third medical visits).
doi:10.1371/journal.pntd.0002004.g001
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Figure 2. Quality of life assessed by ambulatory CHIKV+ve patients* from day 1 until day 14. Three kind of quality of life (health status,
capacity to perform normal activity and quality of sleep) were assessed by self reported visual analogic scale (VAS) from ‘‘very bad’’ (VAS= 0) to ‘‘very
good’’ (VAS= 100) and are represented here by box plot diagrams. Box plot is a representative diagram of continuous variables. The bottom and the
Chikungunya Fever: An Outpatient Investigation
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% of nt mutations, % of variable nt sites and p nt, p,0.05
for dS).
(iii) A comparison of intra-host genetic diversity based on
sequential serum at D1 and D3 from the same patients (nu
304 and nu4002) revealed an increase of genetic diversity
over time (Table 2).
(iv) From the D300 telephone interview, intensity of sequelae
and an increased number of reported arthralgia were
significantly correlated with a higher amino-acid diversity
at inclusion (p aa, dN; p,0.05).
Discussion
Here we have reported a prospective study on Reunion Island
of 54 adult outpatients, examined by general practitioners during
the 2006 CHIK outbreak. These outpatients represent ‘standard’,
‘mild’, clinical presentations (the basis for inclusion was a recent
presentation associating fever and arthralgia), which did not
require hospitalisation or specific treatment for complications.
Such patients represent the majority of cases: the proportion of
hospitalised patients during the CHIKV 2005–2006 outbreak in
Reunion Island was estimated to be 0.3% [12] whilst the majority
of medical investigations were dedicated to hospitalised patients.
Thus our knowledge of severe presentations is currently more
accurate than that of common presentations that do not require
hospitalisation.
On Reunion Island, the epidemiological surveillance system was
based, at first, on active and retrospective case detection around
the reported cases, and then relied on a sentinel network of general
practitioners [24]. Accordingly, some clinical data regarding
outpatients could be collected from cases notified through either
the epidemiological surveillance system [24,25,26], or community
based cross sectional survey [27,28,29,30,31,32,33]. However, the
unique aspect of the current study relies on the detailed clinical
and virological follow-up of such patients. It included laboratory
confirmation of CHIKV infection (based on RT-PCR and
seroconversion), a clinical follow-up at the acute phase (associating
daily auto-questionnaires and medical consultations), and late
assessments (by telephone until day 300). The study took place at
the end of the outbreak (i.e., the enrolment was performed by
practitioners who had previously managed approximately one
third of the population infected by the virus), and there is no
evidence that another arbovirus (e.g. dengue virus) has been
circulating in Reunion Island during this period.
This study has obvious limitations. Firstly, a low patient count:
54 patients, with a confirmed CHIKV infection, was studied on
day 1 (inclusion), but the follow-up was performed for only 27 of
these patients, corresponding to the placebo arm of the clinical
trial. Secondly we could not exclude a potential impact of a
placebo effect during the follow-up. Thirdly, 22 patients with a
negative diagnosis of CHIK (of whom 13 received placebo) were
also included but, regarding outpatients and mild presentations,
the aetiology of their disease could not be further investigated.
Finally, the number of patients for which in depth analysis of intra-
host viral genetic diversity was analysed was low (10 patients) and,
despite interesting and statistically significant results, this specific
aspect will deserve in the future analysis from a larger cohort.
Assessment at inclusion
The clinical presentation of CHIK at inclusion revealed a quite
severe impact of the disease on quality of life, with more than half
of the patients’ scores ,30/100. It conformed with the canonical
presentation previously reported in Reunion Island and in the
recent Indian reports, which included fever and symmetrical poly-
arthralgia [9,10,34,35,36,37,38]. However, this simplistic associ-
ation (fever+polyarthralgia) seems to perform modestly for the
specific diagnosis of CHIK: in a retrospective serologic survey of
the CHIK outbreak in Mayotte Island [28], the PPV was as low as
74%. In our study, despite the great recent clinical experience of
general practitioners, the PPV was similar (71%).
Looking into further details, it appears that arthralgia was most
commonly observed in small joints (i.e., wrists, ankles, hands) and
knees, as reported from both in- and outpatients [9,10,29,34,39].
More precisely, this study highlighted the massive number of
arthralgic joints (16, on average) and the specific importance of (i)
small joint pain such as MCP/PIP or wrist and (ii) a minor or
absent myalgia for the diagnosis of CHIK at the onset of the
disease.
This strongly suggests that a convenient diagnostic score may
profitably guide the diagnosis of CHIK at the acute stage of the
disease. We proposed a very simple and purely clinical score
(Figure 4) which reached 87% PPV in our population (i.e.,
outpatient 18 to 60 years old, examined before the second day of
illness). For convenience, results were categorised as ‘probable’,
‘possible’ and ‘not probable’.
Our data also highlighted the high level of viral load (1.26109
RNA copies/ml on average) at inclusion. It was slightly higher
than in other reports [10,40], possibly due in the current study, to
the very short delay between onset of disease and inclusion. Viral
load at D1 significantly increased with age but no relationship with
clinical presentation or co-morbidity could be identified. In
contrast with previous studies dedicated to hospitalised patients
[9,41], we did not identify a relationship between the level of CRP
and transaminases, a reduction of the polymorphonuclear
neutrophil level or other biological abnormalities, and the intensity
and number of arthralgia or the quality of life at D1. However, as
previously reported from inpatients [10], we observed that
lymphopenia (,1G/L) was closely related to the level of viraemia.
It constituted an important clue for the diagnosis of CHIK as
illustrated by our clinico-biological score (Figure 4), which again,
classified the patients as ‘probable’, ‘possible’ or ‘not probable’, as
a function of the probability to be infected by CHIKV, based on
clinical presentation and lymphocyte count. The PPV of this score
reached 94% in our population, for a threshold of 0.579.
Evolution of the disease
The most original input from the CuraChik protocol was the
detailed information collected (patient self-assessment from D1 to
D14, medical consultations (D1, D7, D25), biological analyses (D1,
D6, D16)), which altogether provided an accurate description of
the evolution of patients during the acute stage of the disease.
top of the box are the 25th and 75th percentile, the band near the middle is the median and the ends of the whiskers are the 1.5 inter-quartile of the
lower and upper quartile. The data not included between the whiskers are plotted as an outlier with small circles (if between 1.5 to 3 inter-quartile of
the lower or upper quartile) or with a star (if higher than 3 inter-quartile of the lower or upper quartile). The outliers are tagged with their patient
numbers to follow them at different time period. * Clinical assessment at D1 was obtained from all CHIKV+ve patients (N = 54) during the Reunion
island outbreak 2005–2006. Only patients receiving placebo (N= 27) were included in D2–D14 clinical assessment.
doi:10.1371/journal.pntd.0002004.g002
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Figure 3. Number and intensity of arthralgic joints for CHIKV+ve* patients. Figure 3A: Self reported number of arthralgic joints reported
per person (day 1–day 14). Figure 3B: Percentage of patients with absent, minimal, moderate or severe arthralgia (day 1–day 14). * Characteristics of
patients included and details of box plots are the same as reported in figure 2.
doi:10.1371/journal.pntd.0002004.g003
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Deciphering these data indicated that the acute disease includes
2 distinct stages
(i) the first (D1–D4, ‘viral stage’) was associated with viraemia,
i.e., clinical symptoms that reflect the viral ‘burst’ and the
initiation of innate immunity, associated with high levels of
pro-inflammatory cytokines [42,43,44] such as interferon-a
and IL-6 but also IL-1Ra, IL-12, IL-15, IP-10 and MCP-1.
This is in coherence with results from Chow et al., who
extended the ‘acute phase’ of the disease until D4 [44]. In all
cases in the current study, this response was associated with a
rapid decrease of viremia from D1 to D3 (39.6% of patients
Figure 4. Clinical and clinico-biological score for the diagnosis of CHIK. These scores were based on patients who reported fever and
arthralgia for less than 48 hours. * MCP+: arthralgia on at least one metacarpophalangeal joint. * W+: arthralgia on at least one wrist. We propose a
clinical score based exclusively on clinical data (W+, MCP+ and Myalgia absent or minor) and a clinico-biological score that further includes
lymphopenia (,1G/L). The result of the score represents the predicted probability to have chikungunya (see calculation of scores in the main text).
doi:10.1371/journal.pntd.0002004.g004
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remained viraemic at D3). In parallel, the clinical presenta-
tion improved promptly: the daily self-assessment, showed a
rapid decrease of the number of arthralgic joints (from 16 to
9) (Figure 3a) and all quality of life parameters dramatically
improved (Figure 2).
(ii) From day 5 to day 14 (‘convalescent stage’), all patients had
no detectable viraemia, but improvement was slower,
considering both quality of life scores (Figure 2) or
rheumatic parameters (Figure 3a, 3b and supporting
information figure S1 and movie S1). The initial
symptoms (e.g., fever and shiver that fell from .80% at D1 to
10% at D7) receded but by the D7 medical visit .40% of
patients had persistent arthralgia, asthenia, myalgia or
headache. Dermatological signs were more often identified
on D7 than D1 (Figure 1), in coherence with studies
reporting skin lesions mostly after disease onset [45,46,47].
This observation may provide an explanation for the large
range of frequency of dermatological signs in the literature
(from 10% to 86%) [4,30]. Previous reports [44] showed that,
by day 10, a number of inflammatory mediators (including
interferon-a, IL-6, IL-1Ra, IL-12, IL-15, IP-10 and MCP-1)
had significantly decreased, at least in patients with initial
high viraemia.
However, despite clinical improvement, it is probable that
immune mechanisms are still involved [48] at this stage. The final
outcome (complete clinical recovery or persistent pain and chronic
joint inflammation) appears likely to depend upon a series of
genetic, viral and immunologic factors that operate at the acute
and convalescent stages. On Reunion Island [31,43] and India
[39] but not Singapore [44], late complications were associated
with severe acute disease. Here, in agreement with the clinical
pattern observed on Reunion Island, patients with a high number
of arthralgic joints at disease onset reported more frequently
persistent arthralgia at D300.
The early and convalescent immune response may be, in
addition to putative yet uncharacterised viral factors, modulated
by innate (genetic) and acquired factors. The latter certainly
include age, which appears in many studies to be a major
determinant of the clinical presentation and outcome. Here, we
found that an increase of age was an independent risk factor for
symptomatic illness at the time of disease onset (number and
intensivity of joint pains) and at D300 (number of cases with
persistent arthralgia). At D300, the patients who did not report
recovery and who reported persistent arthralgia were significantly
older. These results are consistent with studies on hospitalised
patients and Indian report which reported that elderly patients
more frequently presented with atypical feature or a severe course
[10,49,50] with persistent arthralgia [31,39,43,49,50,51].
Genetic factors presumably trigger different immune responses
which may account for the inter-individual and inter-ethnic
variability of clinical presentation. Amongst them, gender is of
specific interest. A single report mentioned a higher susceptibility
of males, to CHIKV infection [52] but globally, previously
published data suggest that symptomatic CHIK is more frequent
in women [35,38]. On Reunion Island, women were over-
represented based on reported cases [24,25] whereas cross
sectional studies, based on representative groups of the population,
found similar seroprevalence values in females and males [32,53].
In two other studies, at the late stage of the disease, female gender
was associated with persistent arthralgia [41] or light cerebral
disorder or fatigue [27]. In the current study, females were
independently associated with a high number of painful joints at
disease onset and at D300. They also reported non-recovery more
frequently at D300. It is difficult at this stage to distinguish
between gender-related specific clinical susceptibility and a
different perception of the disease in males and females.
The interplay between the immune response and viral
evolution most probably constitutes an important issue for disease
outcome. A non-primate animal model [42] showed that CHIKV
could persist much longer than previously believed and such
persistence may imply the existence of specific adapted variants,
or at least depend on the kinetics of viral clearance by the immune
system. To our knowledge, no study had previously described the
intra-host genetic diversity of CHIKV in human samples. We
observed that CHIKV was represented in serum by a variety of
closely related genomes and that genetic diversity increased over
time and was correlated with the decrease of viral load. This
observation relied on the analysis of sequential serum samples
from 2 patients, but was also supported by the analysis of other
sera for which analysis of the intra-host genetic diversity of
CHIKV was made available: the later the serum was sampled, the
higher was the intra-host genetic diversity, based on percentage of
mutant clones and average p aa and dN. These data are
consistent with a mechanism in which acute infection produced
an accumulation of mutations over time (resulting in an increased
intra-host genetic diversity), associated with a lower number of
virions and, possibly, an increased potential for persistence.
Interestingly, we found that a higher amino-acid complexity at the
acute stage was associated with increased reporting of arthralgia
and intensity of sequelae at D300. This may indicate that the
immunological processes associated with the initial viraemia
decline or are partly circumvented, thus enhancing the opportu-
nity for onset of virus persistence and long term clinical
complications. In an experimental model, Coffey et al. previously
observed that a CHIKV variant with high fidelity polymerase
produced truncated viraemia and lower organ titres and suggested
that reduced genetic diversity impacts negatively on virus fitness in
both invertebrate and vertebrate hosts [54]. Moreover in the
macaque model, long-term CHIKV infection was observed in
joints, muscles, lymphoid organs, and liver which could explain
the long-lasting CHIK symptoms observed in humans [42].
Altogether, these data are consistent with the hypothesis that
CHIKV displays increased intra-host diversity which may be
associated with prolonged viraemia, higher organ viral load and
an increased risk of chronic disease. If this is the case, such
mechanisms appear to be quite different from those previously
observed in the case of dengue fever, where lower intra-host
diversity has been associated with more severe cases [55] On the
other hand, our results appear more closely related to previous
reports on the relationship between intra-host genetic diversity,
fitness and virulence in the examples of chronic infections by
induced HIV or HCV [56,57]. Some additional studies are
needed to further characterise the intra-host genetic diversity of
CHIKV at the acute phase of the disease. Sequential analysis
provided by New Generation Sequencing tools may provide a
more accurate picture of this diversity and allow a powerful
analysis of the relationship between the structure and evolution of
intra-host viral genetic diversity and the clinical evolution of
CHIKV infected patients.
Supporting Information
File S1 CuraChik protocol. CuraChik was a randomised double
blind, placebo-controlled, prospective trial aiming at evaluating the
efficacy and safety of chloroquine as therapeutic treatment of CHIK
(http://clinicaltrials.gov/ct2/show/NCT00391313).
(PDF)
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Figure S1 Evolution of the percentage of arthralgia and
health status during the acute stage of CHIK. The size of
the disc for a given joint represents the percentage of arthralgic
patient for this specific joint. The colours of the human figure
represent the mean of the health status of the population studied.
The right column represents the morning assessment from day 2
until day 5 and the left column represents the evening assessment
from day 2 until day 14. Clinical assessment at D1 was obtained
from all CHIKV+ve patients (N= 54). Only patients receiving
placebo (N= 27) were included in D2–D14 clinical assessment.
(TIF)
Movie S1 Evolution of the percentage of arthralgia and
health status during the acute stage of CHIK. The size of
the disc for a given joint represents the percentage of arthralgic
patient for this specific joint. The colours of the human figure
represent the mean of the health status of the population studied.
Only the evening assessments from day 1 to day 14 were included
within this movie. Clinical assessment at D1 was obtained from all
CHIKV+ve patients (N= 54). Only patients receiving placebo
(N= 27) were included in D2–D14 clinical assessment.
(MOV)
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